Celsion Co. (CLSN) Expected to Announce Quarterly Sales of $130,000.00
Equities research analysts expect Celsion Co. (NASDAQ:CLSN) to report sales of $130,000.00 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Celsion’s earnings. Celsion also reported sales of $130,000.00 during the same quarter last year. The business is expected to issue its next quarterly earnings results on Thursday, March 15th.
On average, analysts expect that Celsion will report full-year sales of $130,000.00 for the current fiscal year. For the next fiscal year, analysts anticipate that the firm will report sales of $500,000.00 per share. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that follow Celsion.
Several research firms have recently weighed in on CLSN. Maxim Group raised Celsion from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research note on Wednesday, October 4th. ValuEngine raised Celsion from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 9th. Zacks Investment Research raised Celsion from a “sell” rating to a “hold” rating in a research report on Tuesday, December 19th. Finally, Oppenheimer initiated coverage on Celsion in a research report on Tuesday, November 21st. They set an “outperform” rating and a $9.00 price target on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $11.90.
A hedge fund recently bought a new stake in Celsion stock. Sabby Management LLC purchased a new position in shares of Celsion Co. (NASDAQ:CLSN) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned approximately 1.30% of Celsion as of its most recent filing with the Securities and Exchange Commission. 3.97% of the stock is owned by hedge funds and other institutional investors.
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.